


# Supplemental Figure 1.



**Supplemental Figure 1. Characterization and Vaccine efficacy of rVSV-ZENV constructs in BALB/c mice.** (A) Wild type MEFs were infected with VSV or VSVm at M.O.I. 5. Culture medium was collect 8 or 24 hours post infection and measured for mouse interferon  $\beta$  using Elisa kit (PBL Assay Science). Error bars indicate s.d. (B) Survival percentages of Balb/c mice injected I.M. with rVSVs at 5E7 or 1E8 PFUs. Time point is 28 days after VSV challenge. (C) Diagram showing mouse vaccination and assay procedure. (D) Mice were inoculated intravenously following the procedure above. anti-ZIKV ENV serum titer was analyzed by Elisa using recombinant ZIKV ENV protein and anti-Zika 4G2 antibody was used as standard. (E) Mice were inoculated intramuscularly following the procedure as in (C). anti-Zika ENV serum titer was similarly analyzed as in (D). \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; Student's t-test.


# Supplemental Figure 2.

**A**

**Toxicity Assessment of C57BL/6 Mice**

Virus	Number of mouse	PFU/mouse	Injection Route	% Survival
VSVm	3	1 x 10 <sup>7</sup>	I.V.	100
VSVm-ZprME	3	1 x 10 <sup>7</sup>	I.V.	100

**B**



**Supplemental Figure 2. (A)** Toxicity assessment of rVSVm in C57BL/6 mice through I.V. injection. **(B)** Suckling C57BL/6 mice are susceptible to ZIKV-MR766 infection. Real time PCR analysis of ZIKV in brain tissue of C57BL/6 wild type suckling mice infected with ZIKV-MR766 at 1E6 PFUs for 7 days post infection. Error bars indicate s.d.